Phase 1 Neuroendocrine Tumors Clinical Trials
23 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 23 trials
Recruiting
Phase 1
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Neuroendocrine TumorsNeuroendocrine Carcinoma
Peter Hosein, MD36 enrolled1 locationNCT06889493
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 1
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 1Phase 2
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Hepatocellular CarcinomaNeuroendocrine TumorsGastrointestinal Cancer Metastatic
Teclison Ltd.25 enrolled2 locationsNCT02174549
Recruiting
Phase 1Phase 2
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 1Phase 2
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan49 enrolled11 locationsNCT05048901
Recruiting
Phase 1
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Neuroendocrine TumorsCarcinoma, NeuroendocrineNeuroendocrine Carcinomas+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06041516
Recruiting
Phase 1
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Neuroendocrine TumorsSomatostatin Receptor-positive Neuroendocrine Tumor
University of Wisconsin, Madison10 enrolled1 locationNCT06122610
Recruiting
Phase 1
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Neuroendocrine NeoplasmNeuroendocrine TumorsSST2-positive Neuroendocrine Neoplasms
Crinetics Pharmaceuticals Inc.150 enrolled21 locationsNCT07129252
Recruiting
Phase 1Phase 2
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Neuroendocrine Tumors
Chimeric Therapeutics135 enrolled4 locationsNCT06055439
Recruiting
Phase 1
F-Tryptophan PET/CT in Human Cancers
Breast CancerRectal CancerNeuroendocrine Tumors+2 more
Barbara Ann Karmanos Cancer Institute24 enrolled1 locationNCT05556473
Recruiting
Phase 1
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Breast Cancer MetastaticNeuroendocrine TumorsRenal Cell Carcinoma (RCC)+2 more
SAPU NANO (US) LLC27 enrolled1 locationNCT07369505
Recruiting
Phase 1
Lutathera and ASTX727 in Neuroendocrine Tumours
Neuroendocrine Tumors
Imperial College London27 enrolled1 locationNCT05178693
Recruiting
Phase 1
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Neuroendocrine TumorsSmall Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.22 enrolled1 locationNCT06505824
Recruiting
Phase 1
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Liver CancerPancreatic CancerGastric Cancer+6 more
Arbele Pty Ltd68 enrolled3 locationsNCT05411133
Recruiting
Phase 1
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Erasmus Medical Center24 enrolled1 locationNCT05870423
Recruiting
Phase 1Phase 2
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
Neuroendocrine Tumors
University Hospital, Basel, Switzerland27 enrolled1 locationNCT06455358
Recruiting
Phase 1Phase 2
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Neuroendocrine Tumors
AHS Cancer Control Alberta1,534 enrolled1 locationNCT03145857